On May 27, 2020 Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, reported that Dr. Barbara Klencke, Chief Development Officer, will present the company at the upcoming Jefferies Global Virtual Healthcare Conference and at the Oppenheimer Biotech by the Lake 2020 Investor Summit (Press release, Sierra Oncology, MAY 27, 2020, View Source [SID1234558527]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details:

Conference:

Oppenheimer Biotech by the Lake 2020 Investor Summit

Date:

Thursday, May 28, 2020

Time:

11:25 am. ET

Conference:

Jefferies Global Virtual Healthcare Conference

Date:

Wednesday, June 3, 2020

Time:

4:30 p.m. ET

Webcast:

Listen to a live audio webcast or archive of this presentation at www.sierraoncology.com.